Review





Similar Products

human iga2 isotype control  (InvivoGen)
93
InvivoGen human iga2 isotype control
Human Iga2 Isotype Control, supplied by InvivoGen, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human iga2 isotype control/product/InvivoGen
Average 93 stars, based on 1 article reviews
human iga2 isotype control - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
iga2 fitc  (Miltenyi Biotec)
96
Miltenyi Biotec iga2 fitc
The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
Iga2 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iga2 fitc/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
iga2 fitc - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
mouse anti human iga2 hrp  (SouthernBiotech)
94
SouthernBiotech mouse anti human iga2 hrp
The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
Mouse Anti Human Iga2 Hrp, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human iga2 hrp/product/SouthernBiotech
Average 94 stars, based on 1 article reviews
mouse anti human iga2 hrp - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
anti iga2  (SouthernBiotech)
93
SouthernBiotech anti iga2
The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
Anti Iga2, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti iga2/product/SouthernBiotech
Average 93 stars, based on 1 article reviews
anti iga2 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
iga2  (Moderna)
86
Moderna iga2
The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
Iga2, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iga2/product/Moderna
Average 86 stars, based on 1 article reviews
iga2 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
mrna epgdm1400v9 iga2 surface env glycoprotein  (Moderna)
86
Moderna mrna epgdm1400v9 iga2 surface env glycoprotein
The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
Mrna Epgdm1400v9 Iga2 Surface Env Glycoprotein, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrna epgdm1400v9 iga2 surface env glycoprotein/product/Moderna
Average 86 stars, based on 1 article reviews
mrna epgdm1400v9 iga2 surface env glycoprotein - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
mouse anti human iga2 biot  (SouthernBiotech)
93
SouthernBiotech mouse anti human iga2 biot
The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) <t>IgA</t> in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.
Mouse Anti Human Iga2 Biot, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human iga2 biot/product/SouthernBiotech
Average 93 stars, based on 1 article reviews
mouse anti human iga2 biot - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) IgA in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.

Journal: Scientific Reports

Article Title: SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients

doi: 10.1038/s41598-025-27815-y

Figure Lengend Snippet: The B cell isotypes in the LN and PB compartment, the horizontal black lines indicate the average percentage in both compartments ( a ) IgM in switched B cells, lower in LNs than in PB at 8% (IQR: 5% − 11%) or 13% (IQR: 11% − 26%) ( p = 0.0001), respectively; ( b ) IgM in S-binding B cells, no difference between the LNs and PB at 29% (IQR: 16% − 51%) or 15% (IQR 6% − 33%) ( p = 0.058), respectively; ( c ) IgA in switched B cells, no difference between LNs and PB at 36% (IQR 27% − 43%) or 37% (IQR 32% − 43%) ( p = 0.207), respectively; ( d ) IgA in S-binding B cells, in LNs higher than in PB at 22% (IQR 11% − 32%) or 8% (IQR 5% − 15%) ( p = 0.0002), respectively; ( e ) IgG in switched B cells, in LNs higher than in PB at 49% (IQR 42% − 53%) or 42% (IQR 32% − 48%) ( p = 0.0110), respectively; ( f ) IgG in S-binding B cells, in LNs lower than in PB at 53% (IQR: 44% − 67%) or 73% (IQR 61% − 80%) ( p = 0.0001), respectively. PRM (primary), two vaccinations; BST (booster three), three vaccinations; BSF (booster four), four vaccinations; INFX (infection), prior infection; HYB (hybrid), immunity in which the infection was prior to the last of two vaccinations.

Article Snippet: The following surface mAbs were used: CD19 BV785, CD20 APC-Fire750, CD27 BB700, IgD PE-CF594, CD24 BV650, CD38 BUV563, IgM BUV395, IgG BUV496 (all from BD Biosciences), CXCR3 R718 (eBioscience), IgG1 PE, IgG2 PE, IgG2 FITC, IgG3 FITC (all from SouthernBiotech), IgA PE-Vio770, IgA2 FITC (both from Miltenyi Biotec), and IgA1 PE (Abcam).

Techniques: Binding Assay, Infection